# A Study of BBI503 in Adult Patients With Advanced Urologic Malignancies

> **NCT02232646** · PHASE2 · WITHDRAWN · sponsor: **Sumitomo Pharma America, Inc.**

## Conditions studied

- Urologic Malignancies
- Renal Cell Carcinoma
- Urothelial Carcinoma

## Interventions

- **DRUG:** BBI503

## Key facts

- **NCT ID:** NCT02232646
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-01
- **Primary completion:** 2018-08-01
- **Final completion:** 2018-08-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Low feasibility
- **Last updated:** 2023-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02232646

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02232646, "A Study of BBI503 in Adult Patients With Advanced Urologic Malignancies". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02232646. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*